GW Pharmaceuticals is a world leader in the development of plant-derived cannabinoid therapeutics through its proven drug discovery and development processes, intellectual property portfolio and regulatory and manufacturing expertise. Its pipeline includes Epidiolex for certain rare and severe early-onset, drug-resistant epilepsy syndromes, Sativex, the world’s first prescription medicine derived from the cannabis plant, for the treatment of spasticity due to Multiple Sclerosis, and additional clinical stage cannabinoid product candidates for both orphan and non-orphan indications with a particular focus on neurological conditions.
We believe cannabis holds tremendous promise as a medicinal compound, and companies that can unlock the promise of the plant will have the keys to a very lucrative kingdom. GW has already proven it can deliver and we believe there will be more to come. As a general rule of thumb, we like to own the best of class stocks in a sector – for medical cannabis, that’s GW.